Radio and PodcastLive Radio & PodcastsLoading episode
Fetching episode details...
Radio and PodcastLive Radio & PodcastsRadio and PodcastLive Radio & PodcastsFetching episode details...
Radio and PodcastLive Radio & Podcasts
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? is an episode from GRACEcast by Howard (Jack) West, MD. The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug C...
This episode belongs to GRACEcast.
Use the player on this page to stream the episode online.
Published Jul 17, 2014, 07:28 long, audio available.
Continue listening to more episodes from GRACEcast.
Jul 29, 2014 - 01:55
Jul 24, 2014 - 02:03
Jul 20, 2014 - 04:40
Jul 15, 2014 - 03:15
Jul 13, 2014 - 07:22